Compare Amgen, Inc. (AMGN) vs Five9 Inc (FIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Five9 Inc — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Five9 Inc trades at $25.5 (market cap $1.95B). The key difference: Amgen, Inc. is far larger — about 100.6× Five9 Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Five9 Inc pays none. Which is the better fit depends on your goals.
| AMGN | FIVN | |
|---|---|---|
Market Cap | $196.12B | $1.95B |
Sector | Health | Technology |
52-Week High | $388.16 | $29.16 |
52-Week Low | $271.18 | $13.61 |
Enterprise Value | $241.41B | $2.02B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Five9 (FIVN) trades at $25.42, up 1.97% with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growth from $779M in 2022 to $1.15B in 2025 and a shift to profitability. Recent Q1 2026 earnings beat expectations, and the stock benefits from strong analyst support (61% buy rating) and a $27 consensus price target. However, negative net cash flow and ongoing legal scrutiny present near-term headwinds.
The outlook remains positive given consistent earnings beats and strategic leadership appointments, but risks include insider selling and litigation concerns. Upside potential exists if the company maintains its growth trajectory and addresses cash flow challenges, making it a watch for growth-oriented investors despite volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →
